Entresto Granted Expanded Indication in Chronic Heart Failure by FDA

EAST HANOVER, N.J., Feb. 16, 2021 — Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure.1 Benefits are most clearly evident in patients with left ventricular…

Wearable Sensor Data Predict Heart Failure Rehospitalization

TUESDAY, Feb. 25, 2020 — For patients discharged from heart failure admission, analysis of physiological telemetry data from a wearable sensor can detect worsening heart failure and predict impending rehospitalization, according to a study published online Feb. 25 in Circulation: Heart Failure. Josef Stehlik, M.D., M.P.H., from the VA Salt…

HIV could increase risk of death from heart failure

After a heart failure diagnosis, people who are HIV-positive are more likely to be hospitalized or die of any cause than those not infected with HIV, new research shows. The study is the largest to date to look at how HIV status affects people diagnosed with heart failure, a chronic…